Evidence map›Paper›PMID 26146874›Full record

SynthesisPsychiatric genetics2015

Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system.

Michelle A Patriquin, Isabelle E Bauer, Jair C Soares, David P Graham, David A Nielsen

Registry-linked trialAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Psychiatric genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03018236 (The Effect of N-acetylcysteine), which is not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03018236 phase4unknown statusnot on this mapstarted 2017, after this paper: background citation

The Effect of N-acetylcysteine (NAC) on Treatment of Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.

TypeinterventionalSponsorHospital de Clinicas de Porto AlegreRan2017 to 2018Enrolled100ConditionsCocaine Addiction, Alcohol AddictionArmsAlcohol N-acetylcysteine, Alcohol Placebo, Cocaine N-acetylcysteine, Cocaine Placebo
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 85 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Association of Polymorphism within the Putative miRNA Target Site in the 3'UTR Region of theInternational journal of environmental research and public health · 2022
    Article
  8. Review
  9. Pharmacogenetics of Addiction Therapy.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Pharmacogenetics of Methadone Response.Molecular diagnosis & therapy · 2018
    Review
  20. The frequency ofAnnals of general psychiatry · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Michelle A PatriquinaThe Menninger Clinic bThe Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine cDepartment of Psychiatry and Behavioral Science, University of Texas Health Sciences Center dMichael E. DeBakey Veterans Affairs Medical Center, Houston, Texas USA.
Isabelle E Bauer
Jair C Soares
David P Graham
David A Nielsen
Baylor College of Medicine · USInstitute of Behavioral Sciences · JP

Funding

Tiagabine and Disulfiram for Cocaine DependenceP50DA018197 · NIDA · YALE UNIVERSITY · PI KOSTEN, THOMAS RICHARD · 2004 to 2013
$12.6M
Innovative Multidisciplinary Education: The Statistical Genetics of AddictionR25DA026120 · NIDA · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHANG, SHINE, SHETE, SANJAY · 2010 to 2014
$1.5M
NIDA NIH HHS 5 P50 DA018197-05NIDA NIH HHS DA026120NIDA NIH HHS P50 DA018197NIDA NIH HHS R25 DA026120
6 · The paper itself

Abstract

Substance use disorders have significant personal, familial, and societal consequences. Despite the serious consequences of substance use, only a few therapies are effective in treating substance use disorders, thus highlighting a need for improved treatment practices. Substance use treatment response depends on multiple factors such as genetic, biological, and social factors. It is essential that each component is represented in treatment plans. The dopaminergic system plays a critical role in the pharmacotherapy for addictions, and an understanding of the role of variation of genes involved in this system is essential for its success. This review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement guidelines. A computerized literature search was conducted using PubMed and Scopus (all databases). Articles published up to April 2015 that examined the role of dopaminergic gene variation in the pharmacotherapy of alcohol, opioid, and cocaine use disorders were reviewed. Search terms were dopamine, gene, polymorphism, substance abuse, treatment, and response. Polymorphisms of the DRD2, ANKK1, DAT1, DBH, and DRD4 genes have been found to moderate the effects of pharmacotherapy of alcohol, opioid, and cocaine use disorders. The integration of genetic information with clinical data will inform health professionals of the most efficacious pharmacotherapeutic intervention for substance use disorders. More studies are needed to confirm and extend these findings.

Indexed as

DopamineGenetic Predisposition to DiseaseHumansPharmacogeneticsPolymorphism, GeneticPrecision MedicineSubstance-Related DisordersDopamine

Identifiers

PMID26146874
PMCPMC4549168
OpenAlexW2404405809

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.